• Neucardin®(HFrEF)
  • Neucardin®(HFpEF)
  • Neucardin®(AMI)
  • ZS-05
  • ZS-06
  • ZS-07


Acute Myocardial Infarction(AMI) has high morbidity and mortality around the world. In the United Stated, approximately 450, 000 people die of coronary disease every year. AMI, due to the sharp reduction or interruption of coronary blood supply, can lead to irreversible myocardial cell damage or death. Due to the lack of available treatments, the AMI patient mortality rate remains high.

The data from preclinical studies of Zensun showed that Neucardin® provides protection for ischemic-reperfused animal model myocardial cells. The drug group, showed a significant reduction of myocardial infracted area compared with the placebo and positive control group. Other data from preclinical studies from international academic institutions, organizations and biotechnology companies also supported that Neuregulin1/ErbB4 signaling could induce cardiomyocyte proliferation and repair cardiac injury. Neuregulin signaling molecules could increase cardiac function and reduce infarcted area after myocardial infraction. Neuregulin-1/ErbB signaling pathway activation could improve cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. Overall, data from several preclinical studies from different research centers show that Neucardin® has therapeutic potential for AMI.